Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) kicked off on Tuesday, down -3.40% from the previous trading day, before settling in for the closing price of $69.62. Over the past 52 weeks, ARWR has traded in a range of $9.57-$72.36.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 57.10%. While this was happening, its average annual earnings per share was recorded -31726.54%. With a float of $125.91 million, this company’s outstanding shares have now reached $135.70 million.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arrowhead Pharmaceuticals Inc is 7.29%, while institutional ownership is 81.10%. The most recent insider transaction that took place on Dec 29 ’25, was worth 3,575,575. In this transaction Chief Executive Officer of this company sold 51,726 shares at a rate of $69.13, taking the stock ownership to the 3,805,926 shares. Before that another transaction happened on Dec 26 ’25, when Company’s Director sold 7,530 for $70.00, making the entire transaction worth $527,100. This insider now owns 69,053 shares in total.
Arrowhead Pharmaceuticals Inc (ARWR) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -1.39 earnings per share (EPS), lower than consensus estimate (set at -0.72) by -0.67. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -31726.54% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Take a look at Arrowhead Pharmaceuticals Inc’s (ARWR) current performance indicators. Last quarter, stock had a quick ratio of 4.86. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.01. Likewise, its price to free cash flow for the trailing twelve months is 58.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.07, a number that is poised to hit 0.12 in the next quarter and is forecasted to reach -4.22 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Compared to the last year’s volume of 2.14 million, its volume of 0.97 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 75.77%.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 91.09%, which indicates a significant increase from 60.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.39 in the past 14 days, which was higher than the 2.37 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $51.92, while its 200-day Moving Average is $27.64. Nevertheless, the first resistance level for the watch stands at $69.29 in the near term. At $71.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $73.01. If the price goes on to break the first support level at $65.57, it is likely to go to the next support level at $63.90. Should the price break the second support level, the third support level stands at $61.85.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
The company with the Market Capitalisation of 9.13 billion has total of 135,880K Shares Outstanding. Its annual sales at the moment are 829,450 K in contrast with the sum of -1,630 K annual income. Company’s last quarter sales were recorded 256,470 K and last quarter income was -23,750 K.
